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This study was undertaken in order to determine whether proinﬂammatory cytokines are involved in a previously described protec-
tion against Klebsiella infection mediated by antilipopolysaccharide antibodies. BALB/c mice were infected intraperitoneally with a
lethal challenge of Klebsiella pneumoniae Caroli. One group of mice was protected with monoclonal antibodies against lipopolysac-
charide prior to infection and the second was not. We determined the number of colony-forming units at diﬀerent time points
in the blood of infected animals and paralleled them with plasma levels of ﬁve proinﬂammatory cytokines measured by enzyme
immunoassays. Our results show that the two groups of animals tested expressed diﬀerent plasma concentrations for all cytokines.
The greatest diﬀerence was detected 24 hours after infection, with a higher production in the unprotected group. We concluded that
a reduced cytokine production is partially responsible for the survival of protected animals.
INTRODUCTION
Klebsiella pneumoniae (Kp n e u m o n i a e )i sa ni m p o r -
tant cause of community-acquired and nosocomial in-
fections [1, 2]. In particular, nosocomial pneumonia and
septicemia caused by Klebsiella spp are a frequent problem
in both medical and surgical intensive care units [3, 4].
In spite of the therapeutic eﬀorts to combat severe Kleb-
siella infections, they are still associated with high mor-
tality rates of up to 40% [3, 4] .I no r d e rt oﬁ n da l t e r -
native strategies to prevent or treat these severe infec-
tions, various studies of pathogenicity and characteriza-
tion of possible virulence factors have been performed.
The ﬁnal goal of these studies is to identify surface anti-
gens that might serve as target molecules for active vac-
cination or passive immunotherapy. The most promising
structure for such an approach is the capsular (K) anti-
gen which plays a signiﬁcant role in the pathogenicity of
Kp n e u m o n i a e[5, 6, 7]. Antibodies speciﬁc for K anti-
genmayenhancephagocytosisandprotectagainstexperi-
mental Klebsiella infections [8, 9, 10, 11]. The obstacle for
the successful preparation of such K-antigen-based im-
munologic tool is the fact that there are more than 70
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K antigens expressed on clinical isolates, most of them
presentin1%–2%ofclinicalstrains[12,13].Indeed,Cryz
and coworkers developed a K-antigen-based vaccine con-
taining puriﬁed polysaccharides of 24 capsular serotypes
[14, 15]. A hyperimmune intravenous immunoglobulin
(Ig) preparation made from the postvaccination plasma
of volunteers immunized simultaneously with the Kleb-
siella K antigen and Pseudomonas vaccines has undergone
a randomized clinical trial with intensive care patients
[16]. In that study, the Klebsiella-capsule-speciﬁc Ig ex-
erted signiﬁcant protection. However, the protective ef-
fect was limited to those Klebsiella isolates that belonged
to capsular serogroups included in the vaccine. In that
study the speciﬁed capsule-speciﬁc vaccine covered only
about 70% of the Klebsiella clinical isolates examined, in-
dicating a need for broadening the antibacterial activity
of this product. Another seroepidemiological study in-
dicated that the addition of 10 more K antigens would
broaden the vaccine coverage by only 13% [13]. There-
fore, for the preparation of a more eﬀective Klebsiella vac-
cine such product should probably contain some other
surface determinants with less complex seroepidemiology
than that of the K antigens [17].
Anotherpromisingcandidatesurfacemoleculeforthe
developmentofsuchimmunologictoolisthelipopolysac-
charide (LPS, O antigen). There are several reasons for
such statement. First of all the number of O antigens is
relatively low compared to the number of K antigens [18].2005:2 (2005) Cytokine Response in Klebsiella Infection 89
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Figure 1. Survival curve of BALB/c mice protected with anti-
LPS MAb Ru-O1 (full line) and unprotected mice (dashed line)
after the IP infection with 50 CFU of K pneumoniae Caroli
(O1:K2).
According to literature data the inclusion of only four O
antigens in such preparation would cover more than 70
percent of all clinical Klebsiella isolates [18, 19]. The re-
sults of a recent study suggest that as much as 82% of all
Klebsiella isolates belong to one of the four serogroups:
O1, O2ab, O3, and O5 [20]. On the other hand, it seems
thatagreatproportionofclinicalisolatesshareacommon
epitope located in the core oligosaccharide of the LPS
molecule [21]. In addition, antibodies directed against
LPSwere shown to penetrate thecapsuleof Kp n eu m o n i a e
[22, 23]. Finally, the monoclonal antibody (MAb) against
O1 antigen was shown to be protective in a mouse model
of lethal systemic Klebsiella infection [24].
We have previously described an O-antigen-speciﬁc
murine MAb (clone Ru-O1, immunoglobulin G2b) di-
rected against an immunodominant epitope expressed on
Klebsiella O1,O6,andO8LPSthataremutuallyhighlyre-
lated[12,25,26].O1antigenappearstoplayanimportant
role in clinical strains, being detectable in about one third
of isolates [19, 20, 27]. MAb Ru-O1 expressed high speci-
ﬁcity for the O1 antigen of Klebsiella binding to the out-
ermost partial antigen D-galactan II of the O1 Klebsiella
LPS molecule [19, 24]. They exerted the ability to protect
mice in a murine model of lethal systemic Klebsiella infec-
tion (Figure 1)[ 24]. The exact molecular mechanism of
thisprotectionremainedunknown.Apartoftheirprotec-
tive eﬀect could be contributed to their ability to enhance
opsonization which was demonstrated by in vitro experi-
ments [28]. In addition to promoting phagocytosis, they
may also exert protection by several other mechanisms.
One of the possible mechanisms is the neutralization of
circulating free LPS and thereby modulation of cytokine
production [29, 30]. Straus et al showed that the release
of soluble LPS plays a signiﬁcant role in the pathogene-
sis of Klebsiella-induced lung injury [31, 32]. Cytokines
themselves play the important role in the pathogenesis of
Klebsiella and other gram-negative infections. A signiﬁ-
cant part of the pathogenesis is connected with the eﬀect
of LPS, which was reported responsible for the produc-
tion of several cytokines. The data regarding the role of
some cytokines in the pathogenesis of infections are often
controversial [33].
In the present study, we tried to determine whether
the protective eﬀect of anti-LPS Ru-O1 MAb could be a
consequenceofthemodulatedproductionofsomeproin-
ﬂammatory cytokines that are known to be important
in the pathogenesis of sepsis and septic shock. We an-
alyzed plasma concentrations of interleukin-1β (IL-1β),
interleukin-6 (IL-6), interleukin-12 (IL-12), interferon-γ
(IFN-γ) and tumor necrosis factor alpha (TNF-α) at dif-
ferent time points after a lethal intraperitoneal (IP) bac-
terial challenge with Kp n e u m o n i a eCaroli (O1:K2). The
cytokines production levels were compared with the de-
gree of bacteremia.
MATERIALS AND METHODS
Animals
Eight- to ten-week-old pathogen-free male BALB/c
mice weighing 20 to 25g each were used through study.
Animals were obtained from breeding colony at the Med-
ical Faculty, University of Rijeka. They were kept in plas-
tic cages and given standard laboratory food (Standard
pellets, Faculty of Biotechnology, Domˇ zale, Slovenia) and
water ad libitum. The experiments were conducted ac-
cording to the laws and principles found in the Interna-
tional Guiding Principles of Biomedical Research Involving
Animals by the Council of International Organisations of
Medical Science. The principles are also in accordance
with the Statute for Laboratory Animals of the Croatian
Society for Laboratory Animals.
Bacteria
Experimental infections were performed using the
highly virulent variant of the strain Kp n e u m o n i a eCar-
oli (O1:K2) which has been used before by ourselves [24]
and by other authors as well [9, 11, 34].
ExperimentalKlebsiellainfection
To ensure the virulence of the challenge strain, bac-
teria were injected IP into BALB/c mice and reisolated
from liver and spleen homogenates 24 hours later. For ex-
perimental infection, bacteria grown on blood agar plates
f o r1 8h o u r sw e r es u s p e n d e di ns t e r i l eP B S ,p H7 .4. Bac-
teria were washed two times in PBS to remove loose
slime containing extracellular polysaccharides. Bacterial
suspensions were adjusted densitometrically at 365nm to
thedesiredconcentration,whichwasconﬁrmedbycolony
counts on blood agar plates after serial 10-fold dilutions.
LD50 of Kp n e u m o n i a eCaroli for IP infected mice is 10
organisms per mouse [24]. The experimental groups of
mice were pretreated 4 hours before the infection with an
IPinjectionofpuriﬁedMAbRu-O1atthedoseof40µg/g,
that was previously determined to be protective, or with
PBS. Animals were infected IP with an estimated dose
of 50 organisms of Kp n e u m o n i a eCaroli, corresponding
to ﬁve times the LD50. This dose was selected because,
as described earlier, all animals that were not pretreated
with anti-LPS MAb Ru-O1 died within 4 days, with the90 Tomislav Rukavina et al 2005:2 (2005)
mortality of approximately 50% after 2 days (Figure 1).
Pretreatment with MAb Ru-O1 resulted in 70 percent sur-
vival. The control group of animals was pretreated with
PBS because previous experiments showed no diﬀerence
in mortality between animals pretreated with PBS or ir-
relevant MAb of the IgG2b subclass [24].
QuantiﬁcationofKpneumoniaeCaroliinblood
The degree of bacterial dissemination was detected by
enumeration of Kp n e u m o n i a eCaroli in blood samples.
The animals were euthanized by inhalation of CO2.T h e
blood was obtained by cardiac puncture 2, 6, 12, and 24
hoursafterinfection.Serial10-folddilutionsinsterilePBS
were plated in duplicates on blood agar plates (100µLp e r
plate).Afterincubationat37◦Cfor24hours,coloniesofK
pneumoniae were counted. Bacterial counts are presented
as mean values ± SE of the mean (SEM) colony-forming
units (CFU)/mL.
Plasmacytokineanalyses
Plasma levels of IL-1β, IL-6, IL-12, IFN-γ,a n dT N F - α
were also determined at the time points speciﬁed above.
The blood was obtained by cardiac puncture as described
above. Plasma samples were separated and stored at
−20◦C until assayed. Cytokine concentrations were deter-
mined by commercially available mouse cytokine ELISA
kits (Bender MedSystems, Austria) according to the man-
ufacturer’sinstructions.Accordingtodatasuppliedbythe
manufacturer, detection limits for speciﬁed kits were as
follows: 1.2pg/mLforIL-1β, 12pg/mL for IL-6, 6pg/mL
for IL-12, 8pg/mL for IFN-γ,a n d4 .5pg/mLforTNF-α.
The overall interassay and interassay reproducibility, ex-
pressed by coeﬃcient of variation was declared to be less
than10%forallkitsspeciﬁed.Theresultsarepresentedas
mean values ± SEM of cytokine concentration.
Statisticalanalyses
Statistical signiﬁcance of the diﬀerence between bac-
terial counts and cytokine concentrations of unprotected,
protected, and uninfected control groups were deter-
mined by two-tailed Student t test.
RESULTS
Bacteremia
In order to determine the degree of bacteremia in
unprotected and protected groups of animals, at desig-
nated time points blood bacterial counts were determined
(Figure 2). Unprotected animals had at all time points
higher values than protected animals. The bacteria ap-
peared in blood 2 hours after the infection in a relatively
small amount; 50 ± 21CFU/mL of blood in the unpro-
tected group while bacteremia was not detected in the
protected group. Furthermore, 6 hours after the infec-
tion bacteria were detected in both groups with a signif-
icantly higher number in the unprotected group. Simi-
lar results were recorded also 12 and 24 hours after in-
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Figure 2.ThebacterialcountsinthebloodofBALB/cmicepro-
tected with anti-LPS MAb Ru-O1 (gray bars) and unprotected
mice (white bars) after the IP infection with 50 CFU of Kp n e u -
moniae Caroli (O1:K2) at diﬀerent time points. Results are ex-
pressed as log10 of mean values ± SEM CFU/mL of blood. Six
animals in each group were infected. Statistical signiﬁcance was
found between CFU counts from the groups at all analyzed time
points (P<. 01).
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Figure 3. Plasma concentration of IL-1β in the blood of BALB/c
mice protected with anti-LPS MAb Ru-O1 (gray bars) and un-
protected mice (white bars) after the IP infection with 50 CFU
of K pneumoniae Caroli (O1:K2) at diﬀerent time points. Re-
sults are expressed as mean values ± SEM pg/mL. ∗ and ∗∗
marks above bars represent the statistical signiﬁcance between
the groups at particular time point at the level of P<. 05 and
P<. 01, respectively.
fection. Bacterial counts continuously increased in both
groups with approximately 8-foldhigher values inthe un-
protected group 24 hours after infection (57500 ± 6657
versus 6875 ±1023CFU/mL of blood; P<. 001).
Kineticsofproinﬂammatory
cytokineconcentrations
The levels of diﬀerent proinﬂammatory cytokines in
the plasma of unprotected animals and animals protected
with anti-LPS Ru-O1 MAb, IP infected with Kp n e u m o -
niae Caroli were observed during 24 hours after infection.
Interleukin-1β
Two and six hours after the infection IL-1β concen-
trations were almost the same in both groups (Figure 3).
Plasma levels did not diﬀer signiﬁcantly from values in
uninfected control animals (15 ± 1.9pg/mL).T welveand
twenty-four hours after infection, IL-1β production in
the protected group of animals did not change. On the2005:2 (2005) Cytokine Response in Klebsiella Infection 91
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Figure 4. Plasma concentration of IL-6 in the blood of BALB/c
mice protected with anti-LPS MAb Ru-O1 (gray bars) and un-
protected mice (white bars) after the IP infection with 50 CFU
of K pneumoniae Caroli (O1:K2) at diﬀerent time points. Re-
sults are expressed as mean values ± SEM ng/mL. ∗∗ and ∗∗∗
marks above bars represent the statistical signiﬁcance between
the groups at particular time point at the level of P<. 01 and
P<. 001, respectively.
contrary, plasma concentrations in unprotected animals
increased signiﬁcantly after 12 and 24 hours to the levels
of38±4.8pg/mL(P<. 05)and140±5.6pg/mL(P<. 05),
respectively. Plasma levels of IL-1β diﬀered signiﬁcantly
also between unprotected and protected group of infected
animals 12 and 24 hours after infection (P<. 01 and
p<. 05, respectively). Namely, values in the protected
group remained within the levels in the uninfected con-
trol animals (6 ±1.8a n d3±1.1pg/mL, respectively).
Interleukin-6
IL-6wasnotdetectableintheplasmaoftheuninfected
control group of animals. In both infected groups (Figure
4), 2 hours after the infection plasma levels of IL-6 started
to increase. The concentration was signiﬁcantly higher
in the unprotected group compared to protected animals
(252 ± 20.3v e r s u s7 9± 6.7pg/mL;P<. 01). The amount
of IL-6 further raised in both groups after 6 hours. The
plasma of the protected group contained higher concen-
tration compared to the unprotected animals (2329 ±
155.5 versus 991 ± 144.3pg/mL;P<. 01). Twelve hours
after the infection, plasma level of unprotected animals
continuously increased to the level of 1330 ± 225pg/mL.
IL-6 in this group reached maximal concentration 24
hours after the infection (14.7 ± 0.3ng/mL). On the con-
trary,theconcentrationintheprotectedgroupslightlyde-
creased and remained almost unchanged during the next
12 hours.
Interleukin-12
IL-12 production in both infected groups was al-
most identical with no statistically signiﬁcant diﬀerences
between them (Figure 5). The dynamics of production
showed peak values 24 hours after infection. The diﬀer-
ences for both groups at all time points were statistically
signiﬁcant compared to values of uninfected control mice
(P<. 01).
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Figure 5. Plasma concentration of IL-12 in the blood of BALB/c
mice protected with anti-LPS MAb Ru-O1 (gray bars) and un-
protected mice (white bars) after the IP infection with 50 CFU
of Kpneumoniae Caroli (O1:K2) at diﬀerent time points. Results
are expressed as mean values ± SEM ng/mL.
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Figure6.PlasmaconcentrationofIFN-γ inthebloodofBALB/c
mice protected with anti-LPS MAb Ru-O1 (gray bars) and un-
protected mice (white bars) after the IP infection with 50 CFU
of Kpneumoniae Caroli (O1:K2) at diﬀerent time points. Results
are expressed as mean values ± SEM ng/mL. ∗∗ mark above
bars represents the statistical signiﬁcance between the groups at
particular time point at the level of P<. 01.
Interferon-γ
T h em o d e r a t er i s eo fI F N - γ in unprotected animals
was noticed 6 hours after infection while the level of pro-
tectedmiceremainedwithinvaluesoftheuninfectedcon-
trol group (428±21.2pg/mL)(Figure 6). The production
in both groups reached its maximum 24 hours after infec-
tion. The concentration levels of both groups were signif-
icantly higher compared to uninfected animals (P<. 01).
A signiﬁcant diﬀerence was recorded also for IFN-γ con-
centrations in the plasma from unprotected versus pro-
tected animals with almost 2-fold higher concentration
in unprotected animals compared to the protected group
(P<. 01).
Tumornecrosisfactoralpha
In the unprotected group TNF-α concentration
reached the ﬁrst peak 6 hours after infection and then
slightly decreased (Figure 7) .T h em a x i m u ml e v e lw a s
reached 24 hours after infection. In comparison with the
protected group the concentration of TNF-α was 4 and92 Tomislav Rukavina et al 2005:2 (2005)
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Figure 7. Plasma concentration of TNF-α in the blood of
BALB/c mice protected with anti-LPS MAb Ru-O1 (gray bars)
and unprotected mice (white bars) after the IP infection with 50
CFU of K pneumoniae Caroli (O1:K2) at diﬀerent time points.
Results are expressed as mean values ± SEM ng/mL. ∗∗∗
mark above bars represents the statistical signiﬁcance between
the groups at particular time point at the level of P<. 001.
6 fold higher 6 and 24 hours after infection, respectively.
During the ﬁrst stage of infection the level of TNF-α in-
creased to a much lesser extent in the protected group.
In this group TNF-α production reached maximum value
12 hours after infection and then gradually decreased.
TNF-α levels were signiﬁcantly higher compared to un-
infected control mice level at all time points for both in-
fected groups (P<. 001).
DISCUSSION
We have previously described that anti-LPS MAb Ru-
O1 exerts protection in the model of lethal systemic Kleb-
siella infection [24]. The exact mechanism of this protec-
tion remained unknown. According to our previous re-
search, such eﬀect can be explained partly by enhance-
ment of opsonophagocytosis [28] but we presumed that
t h ee x a c tm o l e c u l a rm e c h a n i s mi sm u c hm o r ec o m p l e x .
There is evidence that several proinﬂammatory cy-
tokinesplayanimportantroleinthepathogenicityofsep-
tic events. As a part of the innate immunity, their role is
to orchestrate an anti-infectious process by enhancing the
microbicidal activities of phagocytic cells, contributing to
therecruitmentofleucocytestowardsthesiteofinfection,
enhancing hematopoiesis, and inducing fever [33]. Many
bacterial compounds activate the production and release
of cytokines, such as LPS. Straus et al reported the impor-
tanceof LPS-containing extracellulartoxic complex in the
pathogenesis of Klebsiella infections [31]. We presumed
thatthiseﬀectisatleastpartlymediatedbythemodulated
proinﬂammatory cytokine response.
In the present study, we tried to determine whether
the protective eﬀect of Ru-O1 MAb could be the con-
sequence of the modulated production of cytokines. We
included some of the most important proinﬂammatory
cytokines in order to determine their kinetics during the
ﬁrst 24 hours after a lethal IP Klebsiella challenge. We did
not analyze later periods since animals in the unprotected
group begun to die between 24 and 48 hours after infec-
tion (Figure 1). We have also analyzed the relation be-
tween cytokine production and the degree of bacteremia.
After the IP challenge, bacteria started to appear in
the blood within the ﬁrst few hours after infection (Figure
2). Our results indicate a diﬀerence between the protected
group (treated previously with Ru-O1 MAb) and the un-
protected group with respect to the dynamics of bacte-
rial appearance. Namely, a low degree of bacteremia was
detectable in the unprotected group 2 hours after infec-
tion while in the protected group it was noticeable after 6
hours (according to our experimental design). We specu-
late that the delayed onset of bacteremia in the protected
group is the consequence of certain events (such as op-
sonophagocytosis) in the peritoneal cavity since the route
of MAb administration and the route of infection were
similar (IP). After the onset, bacteremia continuously in-
creased in both groups and reached the highest level 24
hours after infection with almost 10-fold greater CFU/mL
values in the unprotected group. We reasonably assumed
that the quantity of bacterial compounds released in the
circulation is proportional with the bacterial load. There-
fore, it can be assumed that the unprotected group was
exposed to higher levels of these substances.
Our cytokine assays have shown that the ﬁrst cytokine
that begin to rise in the blood is TNF-α.T w oh o u r sa f -
ter infection its concentration was signiﬁcantly higher in
the protected group of animals compared with the un-
protected group. The fact that it increases ﬁrst among all
the tested cytokines is not a surprise. There is evidence
that TNF, after the LPS challenge in experimental animal
models [35]o ri nh u m a nv o l u n t e e r s[ 36], appears in the
blood before any other cytokine. Moreover, it seems that
TNF is a prerequisite for the production of many other
proinﬂammatory cytokines. Experiments conducted with
anti-TNF antibodies indicated that blocking TNF in bac-
terial or endotoxin-induced shock models led to a dra-
matic decrease in the levels of other cytokines such as IL-
1β,I L - 6 ,a n dI L - 8[ 37, 38]. The explanation for diﬀerent
TNF levels between the groups in our experiment could
be the diﬀerence in the bacterial blood counts and pos-
sibly the neutralization of released LPS and consequently
the neutralization of its eﬀects at the cellular level at the
early stage of infection. We speculate that in the protected
group the stimulation of some receptor structures by the
circulating LPS, such as toll-like receptors, was reduced
and that it led to the reduced TNF production. The TNF
level in the unprotected group continues to increase and
reaches the ﬁrst peak after 6 hours. Such event preceded
the increase of other analyzed cytokines. In the protected
group, the increase of TNF level was not so high, reached
the peak 12 hours after infection, and then gradually de-
creased. It is well documented that TNF production could
have beneﬁcial [39, 40, 41, 42, 43, 44, 45]o rd e t r i m e n -
tal eﬀects [46, 47, 48]i nd i ﬀerent experimental infectious
models. We think that our results are in accordance with
thesefactsandthatTNFlevelsineachexperimentalgroup
canbeconsideredresponsibleforthediﬀerentoutcomeof
infection.2005:2 (2005) Cytokine Response in Klebsiella Infection 93
All other cytokines tested started to appear in greater
amounts after TNF. IL-1β, IL-12, and IFN-γ remained
within or near the limits of the uninfected control group
of mice until 24 hours after infection with the exception
of the moderate increase of IL-1β, 6 hours after infection
in the unprotected group. The increase of IL-6 concentra-
tion is more pronounced. Its concentration reaches, in-
terestingly, after 6 hours more than 2-fold higher values
in the protected group. That result may be of importance
and may contribute to the survival of mice from the pro-
tected group since IL-6 was also described to have anti-
inﬂammatory properties via its capacity to induce the re-
lease of acute-phase proteins [33].
Twenty-four hours after the infection all cytokines in-
cluded in our study reached their highest levels in the un-
protected group, while in the protected group their levels
were much lower. Moreover, IL-1β remained within nor-
mal limits during the whole experiment in the protected
group. The high level of certain proinﬂammatory cy-
tokines alone is associated with a poor outcome of the in-
fection [33, 49]. On the other hand, some of these proin-
ﬂammatory cytokines combined seem to express deleteri-
ous synergistic eﬀect [50]. We speculate that such synergy
betweenthetwoorevenmoreproinﬂammatorycytokines
includedinthestudyisapossibletriggeringfactorthatled
to the mortality in the unprotected group of animals. On
the contrary, the reduction of such synergism can be con-
sidered as contributing factor to the survival of the pro-
t e c t e dg r o u po fa n i m a l s .
Our results led us to a conclusion that the mechanism
of action of Ru-O1 MAb can be explained partially by
the modulation of proinﬂammatory cytokines response
to Klebsiella infection. Their mode of action is certainly
much more complex and further research is necessary for
abetterunderstandingofthisphenomenon.Ourdataem-
phasize the need for broadening the research of anti-LPS
immunity against Klebsiella infections in order to ﬁnd ap-
propriate strategies for the design of a second-generation
Klebsiella vaccine.
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